Back to search results
Laura J. Esserman
Laura J. Esserman

Laura J. Esserman, MD, MBA

Breast Surgical Oncology | Breast Surgery

Breast Care Center
1825 Fourth St., Third Floor,
San Francisco, CA 94158
(415) 353-7070
Virtual visits available
Virtual visits available
Breast Care Center
1825 Fourth St., Third Floor,
San Francisco, CA 94158
(415) 353-7070

Dr. Laura Esserman, a nationally known breast surgeon, directs the UCSF Breast Care Center. Her work is devoted to developing new, more effective ways to care for and empower breast cancer patients during treatment. She tailors treatments for individual patients using biology, personal preference and constant feedback regarding outcomes of care.

Esserman earned her undergraduate degree at Harvard University and completed her medical and surgical training at Stanford University. She completed a postdoctoral fellowship in breast oncology at Stanford and later earned a master's degree from the Stanford Graduate School of Business. She joined UCSF Medical Center in 1993.

  • Board Certifications

    American Board of Surgery, General Surgery

  • Fellowships

    Stanford University School of Medicine, Oncology

  • Residencies

    Stanford University School of Medicine, General Surgery

  • Internship

    Stanford University School of Medicine, General Surgery

  • Degree

    MD, Stanford University School of Medicine

Conditions I specialize in

Where I see patients (1)

    Selected research

    See all research
    Decorative Caduceus

    MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpr...

    Create a large scale registry of full genome expression data with clinical data to investigate possible new gene associations with prognostic or predictive value.

    Recruiting

    Decorative Caduceus

    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    Recruiting

    Decorative Caduceus

    I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

    Time to reach a durable COVID-19 level 4 or less or discharge at COVID-level 4 or lower (except for discharge to another hospital), and time to death (mortality). Data will be analyzed for 3 groups: - All - COVID-19 level...

    Recruiting

    Decorative Caduceus

    Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

    Proportion of cancers diagnosed at Stage IIB or higher

    Recruiting

    My work

    Cutting-edge breast cancer care

    Learn about the latest findings on breast cancer risk, screening and treatment from Dr. Esserman.

    Read the story on ucsf.edu

    Should low-risk tumors still be called cancer?

    Dr. Esserman explains how using a different term could reduce unnecessary worry over cancers that are unlikely to be life-threatening.

    Read the story in Reuters

    Contact me

    Share